Waters Corporation announced a $17.5 billion acquisition of Becton Dickinson’s Biosciences and Diagnostics Solutions business, expanding Waters into molecular testing and clinical diagnostics. The deal aims to double Waters' total addressable market to approximately $40 billion and bolster recurring revenue streams through synergies in biologics, flow cytometry, and lab automation. Industry experts view the move as Waters' strategic response to competitors advancing in molecular diagnostics, notably Bruker’s recent acquisitions. The acquisition is expected to close next year, with Waters CEO Udit Batra leading the combined entity.